ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 183.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,445 shares of the company’s stock after acquiring an additional 8,050 shares during the period. JPMorgan Chase & Co.’s holdings in ArriVent BioPharma were worth $292,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Novo Holdings A S grew its position in shares of ArriVent BioPharma by 0.4% in the third quarter. Novo Holdings A S now owns 1,505,315 shares of the company’s stock valued at $35,375,000 after purchasing an additional 5,315 shares during the period. BNP Paribas Financial Markets boosted its holdings in ArriVent BioPharma by 32.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company’s stock worth $516,000 after buying an additional 5,397 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in ArriVent BioPharma during the 3rd quarter worth approximately $240,000. MetLife Investment Management LLC raised its holdings in shares of ArriVent BioPharma by 168.9% during the third quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock valued at $384,000 after acquiring an additional 10,269 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of ArriVent BioPharma in the third quarter valued at approximately $280,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their price objective on ArriVent BioPharma from $36.00 to $39.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, ArriVent BioPharma presently has an average rating of “Buy” and a consensus target price of $37.40.

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock opened at $29.09 on Friday. The stock’s 50 day simple moving average is $27.12 and its 200-day simple moving average is $26.32. ArriVent BioPharma, Inc. has a 1-year low of $14.35 and a 1-year high of $36.37.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.